Zhejiang Jingxin Pharmaceutical Co., Ltd. Stock price

Equities

002020

CNE000001K73

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
10.88 CNY +2.84% Intraday chart for Zhejiang Jingxin Pharmaceutical Co., Ltd. -4.39% -14.47%
Sales 2023 * 4.02B 556M Sales 2024 * 4.56B 631M Capitalization 9.37B 1.3B
Net income 2023 * 676M 93.56M Net income 2024 * 756M 105M EV / Sales 2023 * 2.33 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 2.05 x
P/E ratio 2023 *
13.9 x
P/E ratio 2024 *
12.4 x
Employees 4,101
Yield 2023 *
-
Yield 2024 *
-
Free-Float 57.17%
More Fundamentals * Assessed data
Dynamic Chart
Evotec Says Partner Obtained Regulatory Approval in China for Insomnia Drug MT
Jingxin Pharmaceutical Gets Nod to Market Didacinil Capsules MT
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jingxin Pharma's Unit Gets Nod to Market Eye Drug in Europe MT
ExoRNA Bio announced that it has received funding from Guangzhou Yuexiu Industrial Investment Fund Management Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., Dingxin Capital Co., Ltd., CDH Investment Management Company Limited and other investors CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Directorate Appointments CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. signed an agreement to acquire Guangdong Shaxi Pharmaceutical Co., Ltd. from Jingxin Holding Group Co., Ltd. and Xinchang Yuanjin Health Industry Investment Partnership Enterprise (Limited Partnership) for approximately CNY 210 million. CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news
1 day+2.84%
1 week-4.39%
Current month+0.46%
1 month-0.46%
3 months-12.47%
6 months-11.40%
Current year-14.47%
More quotes
1 week
10.52
Extreme 10.52
11.28
1 month
10.24
Extreme 10.24
11.46
Current year
8.28
Extreme 8.28
12.93
1 year
8.28
Extreme 8.28
16.16
3 years
7.57
Extreme 7.57
16.16
5 years
7.57
Extreme 7.57
16.16
10 years
6.15
Extreme 6.1458
16.16
More quotes
Managers TitleAgeSince
Chairman 60 -
Director of Finance/CFO 54 -
Chairman 62 -
Members of the board TitleAgeSince
Chairman 62 -
Director/Board Member 61 22-10-12
Director of Finance/CFO 54 -
More insiders
Date Price Change Volume
24-03-27 10.88 +2.84% 10 634 250
24-03-27 10.58 -2.49% 8,705,254
24-03-26 10.85 +0.93% 9,756,860
24-03-25 10.75 -3.33% 12,666,010
24-03-22 11.12 -1.59% 12,875,570

End-of-day quote Shenzhen S.E., March 27, 2024

More quotes
ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. is a China-based company engaged in manufacture of pharmaceuticals. The Company's pharmaceutical products include chemical pharmaceuticals, traditional medicines, biological agents and bulk pharmaceutical chemicals. Its pharmaceutical products are mainly applied in cardiovascular sector, digestive tract sector and psychoneural sector, among others. The Company is also engaged in the research and development, manufacture and sales of medical devices. Its medical devices include clinical displays, diagnosis displays, endoscopic surgery displays and ultrasonic image displays, among others. The Company operates its businesses in both domestic and overseas markets.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.88
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Zhejiang Jingxin Pharmaceutical Co., Ltd. - Shenzhen S.E.